论文信息 - Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. - 字舞流文

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

H. Kantarjian | J. Cortes | S. Verstovsek | M. Wadleigh | C. Tam | Catherine C. Smith | N. Shah | L. Sokol | D. Clary | Patrycja Olszynski | L. Bui | Chunyan Song